To overcome pharmacologic and cytokinetic resistance to cytarabine in the treatment of acute myelogenous leukemia by using recombinant interleukin-3?
Brach
M A
MA
Department of Hematology and Oncology, University of Freiburg Medical Center, Germany.
Henschler
R
R
Mertelsmann
R
R
Herrmann
F
F
D000971:Antineoplastic Combined Chemotherapy Protocols; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D007377:Interleukin-3 / Q000627:therapeutic use*; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D007377:Interleukin-3; D011994:Recombinant Proteins; D003561:Cytarabine